[S02DA03, antipyrine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Streptokinase.]
[J01GA01, streptomycin, Indomethacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indomethacin.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Streptozocin.]
[L04AA27, fingolimod, Indomethacin may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Indomethacin.]
[A02BX02, sucralfate, Indomethacin may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Indomethacin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Indomethacin can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Indomethacin.]
[J01EC03, sulfamoxole, The metabolism of Indomethacin can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Indomethacin can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Indomethacin is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sulindac.]
[M01AE07, suprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mercaptopurine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Indomethacin.]
[N05CD07, temazepam, Indomethacin may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Indomethacin is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The excretion of Indomethacin can be increased when combined with Testosterone.]
[S03AA02, tetracycline, The excretion of Tetracycline can be decreased when combined with Indomethacin.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Indomethacin is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Indomethacin can be decreased when combined with Dronabinol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Thalidomide.]
[P02CA02, thiabendazole, Indomethacin may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Eribulin.]
[R06AD03, thiethylperazine, Indomethacin may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Indomethacin is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tioguanine.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Thioridazine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Indomethacin is combined with Moxisylyte.]
[N05AL03, tiapride, Indomethacin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Indomethacin is combined with Ticlopidine.]
[S01ED01, timolol, Indomethacin may decrease the antihypertensive activities of Timolol.]
[P01AB02, tinidazole, Indomethacin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Indomethacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Tolazamide.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be decreased when used in combination with Indomethacin.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tolmetin.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Indomethacin.]
[N06AF04, tranylcypromine, The metabolism of Indomethacin can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Indomethacin is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Indomethacin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Indomethacin.]
[C03DB02, triamterene, Indomethacin may increase the nephrotoxic activities of Triamterene.]
[N05CD05, triazolam, Indomethacin may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Indomethacin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Trifluoperazine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Trifluridine.]
[D07AC02, fluclorolone, The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Indomethacin.]
[R03BA07, mometasone, The risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Indomethacin.]
[A03AA05, trimebutine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Trimebutine.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Trimethadione.]
[C02BA01, trimethaphan, The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Indomethacin.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of gastrointestinal bleeding can be increased when Trimipramine is combined with Indomethacin.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Indomethacin is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Indomethacin.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Indomethacin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Belimumab.]
[L01FX04, ipilimumab, Indomethacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Indomethacin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Linagliptin.]
[J05AG05, rilpivirine, The metabolism of Indomethacin can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Urokinase.]
[S01AA28, vancomycin, Indomethacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Indomethacin is combined with Belatacept.]
[N03AX21, ezogabine, The metabolism of Ezogabine can be decreased when combined with Indomethacin.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Rivaroxaban.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Indomethacin.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Ticagrelor.]
[C08DA01, verapamil, Indomethacin may decrease the excretion rate of Verapamil which could result in a higher serum level.]
[N06AX09, viloxazine, Indomethacin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Vinblastine.]
[C04AX07, vincamine, The therapeutic efficacy of Vincamine can be decreased when used in combination with Indomethacin.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Vincristine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Indomethacin.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Indomethacin.]
[B01AA03, warfarin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Warfarin.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Indomethacin is combined with Xenon.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Indomethacin.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Zidovudine is combined with Indomethacin.]
[N05AF05, zuclopenthixol, The risk or severity of hypertension can be increased when Indomethacin is combined with Zuclopenthixol.]
[J05AE02, indinavir, Indinavir may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[L01EC01, vemurafenib, The metabolism of Indomethacin can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Pamidronic acid.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, The serum concentration of Tiludronic acid can be increased when it is combined with Indomethacin.]
[B06AC02, icatibant, Indomethacin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.]
[R03DC01, zafirlukast, The metabolism of Indomethacin can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Indomethacin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate.]
[J01MA13, trovafloxacin, Indomethacin may increase the neuroexcitatory activities of Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of hypertension can be increased when Ziprasidone is combined with Indomethacin.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Drospirenone.]
[V03AC02, deferiprone, Indomethacin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Indomethacin.]
[N02BA01, aspirin, The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Indomethacin.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ruxolitinib.]
[G04BD07, tolterodine, Indomethacin may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Indomethacin.]
[C07AB03, atenolol, Indomethacin may decrease the antihypertensive activities of Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Indomethacin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Indomethacin.]
[J02AC03, voriconazole, The serum concentration of Indomethacin can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, Indomethacin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[M01CB03, auranofin, Indomethacin may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Indomethacin.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Indomethacin.]
[S01EE05, tafluprost, The therapeutic efficacy of Tafluprost can be decreased when used in combination with Indomethacin.]
[H02AB11, prednylidene, The risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Indomethacin.]
[B03XA04, peginesatide, Indomethacin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Gemcitabine.]
[J01DF01, aztreonam, Indomethacin may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Bacitracin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Indomethacin.]
[M03BX01, baclofen, Indomethacin may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Indomethacin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Indomethacin.]
[A08AA11, lorcaserin, Indomethacin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Indomethacin is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Carfilzomib.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Indomethacin.]
[L02BB04, enzalutamide, The serum concentration of Indomethacin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Octopamine.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Indomethacin is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Indomethacin.]
[L01EX05, regorafenib, The metabolism of Indomethacin can be decreased when combined with Regorafenib.]
[D02BA02, octinoxate, Indomethacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Indomethacin can be increased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bendamustine.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Indomethacin is combined with Rasagiline.]
[C08CA13, lercanidipine, The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Indomethacin.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Indomethacin.]
[L04AA29, tofacitinib, Indomethacin may increase the immunosuppressive activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Zolmitriptan is combined with Indomethacin.]
[V09IX04, fluorodeoxyglucose F18, Indomethacin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Indomethacin is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Indomethacin.]
[H01CB05, pasireotide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Indomethacin can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Indomethacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ponatinib.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Apixaban.]
[A16AX08, teduglutide, Indomethacin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Indomethacin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Indomethacin.]
[N02BA10, benorilate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, Indomethacin may increase the neuroexcitatory activities of Gemifloxacin.]
[M04AB03, benzbromarone, Indomethacin may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, Indomethacin may increase the neuroexcitatory activities of Moxifloxacin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Pramlintide.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Indomethacin.]
[L03AA12, ancestim, Indomethacin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Indomethacin is combined with Naratriptan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Indomethacin is combined with Everolimus.]
[N04AC01, benztropine, Indomethacin may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[L01EC02, dabrafenib, The serum concentration of Indomethacin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Benzydamine.]
[L01EE01, trametinib, Indomethacin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Indomethacin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Indomethacin.]
[J05AJ03, dolutegravir, The excretion of Indomethacin can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The therapeutic efficacy of Bepridil can be decreased when used in combination with Indomethacin.]
[C02KX05, riociguat, The therapeutic efficacy of Riociguat can be decreased when used in combination with Indomethacin.]
[L03AA14, lipegfilgrastim, Indomethacin may increase the myelosuppressive activities of Lipegfilgrastim.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Lixisenatide.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be decreased when combined with Indomethacin.]
[C02KX04, macitentan, The therapeutic efficacy of Macitentan can be decreased when used in combination with Indomethacin.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibrutinib.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Indomethacin is combined with Vortioxetine.]
[G03AC08, etonogestrel, Indomethacin may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The metabolism of Eslicarbazepine can be decreased when combined with Indomethacin.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[J05AP08, sofosbuvir, Indomethacin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Indomethacin is combined with Droxidopa.]
[C07AB04, acebutolol, Indomethacin may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, Indomethacin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, The metabolism of Indomethacin can be increased when combined with Apremilast.]
[L02BG02, formestane, Indomethacin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Indomethacin.]
[S01ED02, betaxolol, Indomethacin may decrease the antihypertensive activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Argatroban.]
[V03AB34, fomepizole, Indomethacin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Indomethacin.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Indomethacin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Indomethacin can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Vorapaxar.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Vedolizumab.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Belinostat can be decreased when combined with Indomethacin.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Idelalisib.]
[N07XX08, tafamidis, The excretion of Indomethacin can be decreased when combined with Tafamidis.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Indomethacin is combined with Peginterferon beta-1a.]
[V08AA01, diatrizoic acid, Indomethacin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01EE02, unoprostone, The therapeutic efficacy of Unoprostone can be decreased when used in combination with Indomethacin.]
[V08AA04, iothalamic acid, Indomethacin may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[J01XA05, oritavancin, The metabolism of Indomethacin can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Dihydrostreptomycin.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Acepromazine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Indomethacin.]
[S03AA06, gentamicin, Indomethacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Blinatumomab.]
[J05AP09, dasabuvir, The metabolism of Indomethacin can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Edoxaban.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Indomethacin is combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Indomethacin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Palbociclib.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Indomethacin is combined with Panobinostat.]
[N02BE01, acetaminophen, The risk or severity of adverse effects can be increased when Acetaminophen is combined with Indomethacin.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Indomethacin.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The excretion of Asunaprevir can be decreased when combined with Indomethacin.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Indomethacin.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of hypertension can be increased when Indomethacin is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Indomethacin is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Cariprazine.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Acemetacin.]
[S01EC01, acetazolamide, The excretion of Indomethacin can be decreased when combined with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin degludec.]
[A02BC03, lansoprazole, The excretion of Indomethacin can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Indomethacin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Indomethacin can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, Indomethacin may increase the nephrotoxic activities of Tenofovir alafenamide.]
[L01XG03, ixazomib, Indomethacin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The therapeutic efficacy of Selexipag can be decreased when used in combination with Indomethacin.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Acetohexamide.]
[M04AB05, lesinurad, Indomethacin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP11, grazoprevir, The excretion of Grazoprevir can be decreased when combined with Indomethacin.]
[M01AE16, alminoprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Alminoprofen.]
[N02BA02, aloxiprin, The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Indomethacin.]
[N03AX23, brivaracetam, Indomethacin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ixekizumab.]
[N05BA08, bromazepam, Indomethacin may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Indomethacin may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[N06AA19, amineptin, The risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Indomethacin.]
[C08CA01, amlodipine, Indomethacin may decrease the antihypertensive activities of Amlodipine.]
[M02AA09, bufexamac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bufexamac.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Indomethacin.]
[N01BB01, bupivacaine, Indomethacin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, Indomethacin may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Indomethacin.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Indomethacin is combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Indomethacin is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Indomethacin.]
[P01BE03, artesunate, The metabolism of Artesunate can be decreased when combined with Indomethacin.]
[M02AA03, clofezone, Indomethacin may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[J01MA09, sparfloxacin, Indomethacin may increase the neuroexcitatory activities of Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Indomethacin.]
[L01XK03, rucaparib, The metabolism of Indomethacin can be decreased when combined with Rucaparib.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Brodalumab.]
[A07EC04, balsalazide, The therapeutic efficacy of Balsalazide can be decreased when used in combination with Indomethacin.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Bambuterol.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Indomethacin.]
[A06AH05, naldemedine, Indomethacin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Indomethacin may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Indomethacin.]
[C09AA07, benazepril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Benazepril.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Benfluorex.]
[P01CA02, benznidazole, Indomethacin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Linezolid.]
[J05AF06, abacavir, The metabolism of Abacavir can be decreased when combined with Indomethacin.]
[J05AE09, tipranavir, Tipranavir may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N07XX13, valbenazine, Indomethacin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Indomethacin can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Indomethacin is combined with Safinamide.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sarilumab.]
[J01MA23, delafloxacin, The metabolism of Delafloxacin can be decreased when combined with Indomethacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Indomethacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Indomethacin.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Indomethacin is combined with Vorinostat.]
[C07AB07, bisoprolol, Indomethacin may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Indomethacin can be increased when combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefprozil.]
[C07AA17, bopindolol, Indomethacin may decrease the antihypertensive activities of Bopindolol.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Indomethacin.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Indomethacin.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Indomethacin.]
[S01BC11, bromfenac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bromfenac.]
[C03DA03, canrenone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Canrenone.]
[R03BA02, budesonide, The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Indomethacin.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Indomethacin is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Bumadizone.]
[S01EE06, latanoprostene bunod, The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Indomethacin.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of gastrointestinal bleeding can be increased when Butriptyline is combined with Indomethacin.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be increased when it is combined with Indomethacin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Ertugliflozin.]
[R06AX18, acrivastine, Indomethacin may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Indomethacin.]
[L02BB05, apalutamide, The excretion of Indomethacin can be decreased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Carbamazepine.]
[J01CA03, carbenicillin, The excretion of Indomethacin can be decreased when combined with Carbenicillin.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Indomethacin.]
[C07AG02, carvedilol, Indomethacin may decrease the antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Indomethacin can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Indomethacin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The excretion of Indomethacin can be decreased when combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Indomethacin.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefpodoxime.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Indomethacin.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Indomethacin.]
[J01GB14, plazomicin, Indomethacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Indomethacin may decrease the antihypertensive activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Indomethacin.]
[L01XX62, ivosidenib, The metabolism of Indomethacin can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, The metabolism of Migalastat can be decreased when combined with Indomethacin.]
[N03AX17, stiripentol, The metabolism of Indomethacin can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Indomethacin can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, Indomethacin may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Carbutamide.]
[D08AE05, chloroxylenol, Indomethacin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of adverse effects can be increased when Indomethacin is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Inotersen.]
[R03BB08, revefenacin, Indomethacin may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L04AA39, emapalumab, The metabolism of Indomethacin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Indomethacin.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ravulizumab.]
[A06AX05, prucalopride, Indomethacin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Indomethacin is combined with Caplacizumab.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Indomethacin.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Indomethacin is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Indomethacin can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Indomethacin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Indomethacin is combined with Siponimod.]
[J01FA09, clarithromycin, Indomethacin may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Indomethacin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Indomethacin.]
[N05BA09, clobazam, Indomethacin may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Indomethacin.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Ubidecarenone.]
[C09CA06, candesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Indomethacin.]
[L04AB01, etanercept, The metabolism of Indomethacin can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Indomethacin.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Indomethacin can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The excretion of Cefaclor can be decreased when combined with Indomethacin.]
[J01DB05, cefadroxil, The excretion of Indomethacin can be decreased when combined with Cefadroxil.]
[J01DC03, cefamandole, The excretion of Indomethacin can be decreased when combined with Cefamandole.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefatrizine.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Indomethacin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Indomethacin.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Indomethacin.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefonicid.]
[L01EX15, pexidartinib, The metabolism of Indomethacin can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, The excretion of Indomethacin can be decreased when combined with Cefoperazone.]
[J01DD01, cefotaxime, The excretion of Indomethacin can be decreased when combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefotetan.]
[J01DC07, cefotiam, The excretion of Indomethacin can be decreased when combined with Cefotiam.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Ceftazidime.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Indomethacin.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Indomethacin.]
[J01DD04, ceftriaxone, The excretion of Indomethacin can be decreased when combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefuroxime.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Upadacitinib.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pitolisant.]
[N04CX01, istradefylline, The excretion of Indomethacin can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Indomethacin is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin pork.]
[J01XX09, daptomycin, Indomethacin may decrease the excretion rate of Daptomycin which could result in a higher serum level.]
[J01DB01, cephalexin, The excretion of Cephalexin can be decreased when combined with Indomethacin.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Indomethacin.]
[J01DB03, cephalothin, The excretion of Indomethacin can be decreased when combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Indomethacin.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Indomethacin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Diroximel fumarate.]
[G03AC09, desogestrel, The metabolism of Indomethacin can be increased when combined with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Indomethacin.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Indomethacin.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Givosiran.]
[M09AX08, golodirsen, Indomethacin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Indomethacin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The metabolism of Indomethacin can be decreased when combined with Avapritinib.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Indomethacin.]
[M01AX21, diacetylrhein, The metabolism of Indomethacin can be decreased when combined with Diacerein.]
[C10AX15, bempedoic acid, The metabolism of Bempedoic acid can be decreased when combined with Indomethacin.]
[S01AE06, gatifloxacin, Indomethacin may increase the neuroexcitatory activities of Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Indomethacin.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Indomethacin is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Indomethacin is combined with Dutasteride.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ozanimod.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Indomethacin.]
[R02AA03, dichlorobenzyl alcohol, Indomethacin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Indomethacin may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Indomethacin.]
[M01AH02, rofecoxib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Indomethacin.]
[C08CA16, clevidipine, The metabolism of Indomethacin can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The excretion of Indomethacin can be decreased when combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Indomethacin.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Indomethacin is combined with Chloramphenicol.]
[C02AA06, methoserpidine, The therapeutic efficacy of Methoserpidine can be decreased when used in combination with Indomethacin.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be increased when it is combined with Indomethacin.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Indomethacin.]
[M01AC04, droxicam, The risk or severity of adverse effects can be increased when Indomethacin is combined with Droxicam.]
[V08CA05, mangafodipir, Indomethacin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Indomethacin is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexketoprofen.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Indomethacin is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Stepronin.]
[C08CA17, levamlodipine, The therapeutic efficacy of Levamlodipine can be decreased when used in combination with Indomethacin.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Indomethacin.]
[L01FX15, belantamab mafodotin, Indomethacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Indomethacin can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, Indomethacin may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Indomethacin.]
[M03BB03, chlorzoxazone, Indomethacin may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Indomethacin.]
[N02BA07, ethenzamide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Indomethacin.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Etofenamate.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Indomethacin.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Fludarabine.]
[M01AX25, chondroitin sulfates, Indomethacin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Indomethacin is combined with Naxitamab.]
[J05AJ04, cabotegravir, The excretion of Indomethacin can be decreased when combined with Cabotegravir.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Voclosporin.]
[L01EX21, tepotinib, The metabolism of Indomethacin can be decreased when combined with Tepotinib.]
[N03AX10, felbamate, The metabolism of Indomethacin can be decreased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Indomethacin.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Indomethacin is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Indomethacin is combined with Finasteride.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Indomethacin.]
[J01MB07, flumequine, Indomethacin may increase the neuroexcitatory activities of Flumequine.]
[R03BA03, flunisolide, The risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Indomethacin.]
[S02BA08, fluocinolone acetonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Indomethacin.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Indomethacin.]
[N02BG07, flupirtine, Indomethacin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ponesimod.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Indomethacin is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Indomethacin.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Dasiglucagon can be decreased when used in combination with Indomethacin.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[V08CA04, gadoteridol, Indomethacin may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Cinnarizine.]
[J01MB06, cinoxacin, Indomethacin may increase the neuroexcitatory activities of Cinoxacin.]
[S03AA07, ciprofloxacin, Indomethacin may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Indomethacin.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pegcetacoplan.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Finerenone.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Indomethacin is combined with Belumosudil.]
[P01CA03, fexinidazole, The excretion of Indomethacin can be decreased when combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Anifrolumab.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Indomethacin.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Indomethacin.]
[V09AB03, ioflupane I-123, Indomethacin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Indomethacin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Indomethacin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Clenbuterol.]
[L01EA06, asciminib, The metabolism of Indomethacin can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Indomethacin.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tenecteplase.]
[B06AX04, mitapivat, The metabolism of Indomethacin can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Indomethacin may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA04, clomipramine, The risk or severity of gastrointestinal bleeding can be increased when Clomipramine is combined with Indomethacin.]
[N03AE01, clonazepam, Indomethacin may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The therapeutic efficacy of Clonidine can be decreased when used in combination with Indomethacin.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Indomethacin.]
[C01EB24, mavacamten, The serum concentration of Indomethacin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Indomethacin.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Tirzepatide.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Indomethacin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Indomethacin.]
[M02AA08, felbinac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Felbinac.]
[N05AH02, clozapine, The risk or severity of neutropenia can be increased when Indomethacin is combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Sotagliflozin.]
[J01GB12, arbekacin, Indomethacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[C02KB01, metyrosine, The therapeutic efficacy of Metyrosine can be decreased when used in combination with Indomethacin.]
[L04AC21, bimekizumab, The metabolism of Indomethacin can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Proquazone.]
[R05DA04, codeine, The excretion of Indomethacin can be decreased when combined with Codeine.]
[M04AC01, colchicine, Indomethacin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, Indomethacin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefpirome.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Indomethacin is combined with Desflurane.]
[A04AA03, tropisetron, Indomethacin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Indomethacin is combined with Ifenprodil.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Mecasermin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Nelarabine.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin glargine.]
[R03BA08, ciclesonide, The risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Indomethacin.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Indobufen.]
[J05AB14, valganciclovir, Indomethacin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Indomethacin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Indomethacin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Indomethacin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Indomethacin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Indomethacin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Valdecoxib.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Indomethacin.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Indomethacin is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Indomethacin is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Bemiparin.]
[S01AD03, acyclovir, The excretion of Acyclovir can be decreased when combined with Indomethacin.]
[N05BA10, ketazolam, Indomethacin may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Kebuzone.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be decreased when combined with Indomethacin.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Imatinib.]
[A02BC05, esomeprazole, The excretion of Indomethacin can be decreased when combined with Esomeprazole.]
[S01EE04, travoprost, The therapeutic efficacy of Travoprost can be decreased when used in combination with Indomethacin.]
[S01EE03, bimatoprost, The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Indomethacin.]
[C08CA09, lacidipine, The therapeutic efficacy of Lacidipine can be decreased when used in combination with Indomethacin.]
[N03AX09, lamotrigine, The metabolism of Indomethacin can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Indomethacin.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Indomethacin.]
[S01AE04, lomefloxacin, Indomethacin may increase the neuroexcitatory activities of Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Lonazolac.]
[R06AX13, loratadine, Indomethacin may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Loracarbef.]
[C09AA03, lisinopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, Indomethacin may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The therapeutic efficacy of Manidipine can be decreased when used in combination with Indomethacin.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Indomethacin is combined with Mefenorex.]
[C07AA14, mepindolol, Indomethacin may decrease the antihypertensive activities of Mepindolol.]
[H02AB15, meprednisone, The risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Indomethacin.]
[J01DH02, meropenem, Indomethacin may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The metabolism of Indomethacin can be decreased when combined with Cyclizine.]
[S01BC10, nepafenac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Nepafenac.]
[C03DA04, eplerenone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Eplerenone.]
[N05AD03, metylperon, Indomethacin may decrease the excretion rate of Melperone which could result in a higher serum level.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Indomethacin.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Miglitol.]
[J05AF07, tenofovir disoproxil, Indomethacin may increase the nephrotoxic activities of Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Indomethacin is combined with Minaprine.]
[S01XA18, cyclosporine, Indomethacin may increase the immunosuppressive activities of Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Indomethacin is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Indomethacin can be decreased when combined with Modafinil.]
[C09AA13, moexipril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Moexipril.]
[C10AA07, rosuvastatin, The excretion of Rosuvastatin can be decreased when combined with Indomethacin.]
[M02AA02, mofebutazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Morniflumate.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Indomethacin.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dactinomycin.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Indomethacin can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin.]
[C02CC04, debrisoquin, The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Indomethacin.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Indomethacin.]
[M01AX01, nabumetone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Nabumetone.]
[N07BB05, nalmefene, The metabolism of Nalmefene can be decreased when combined with Indomethacin.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Indomethacin.]
[C07AB12, nebivolol, Indomethacin may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Indomethacin may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of gastrointestinal bleeding can be increased when Nefazodone is combined with Indomethacin.]
[C01DX16, nicorandil, The therapeutic efficacy of Nicorandil can be decreased when used in combination with Indomethacin.]
[L02BB02, nilutamide, The metabolism of Indomethacin can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Indomethacin.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Indomethacin is combined with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Norfenefrine.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Fondaparinux.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Indomethacin.]
[N06AB10, escitalopram, The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Indomethacin.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Solifenacin.]
[A07EC03, olsalazine, The therapeutic efficacy of Olsalazine can be decreased when used in combination with Indomethacin.]
[N06AA01, desipramine, The risk or severity of gastrointestinal bleeding can be increased when Desipramine is combined with Indomethacin.]
[H01BA02, desmopressin, The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Indomethacin is combined with Desmopressin.]
[D07XC02, desoximetasone, The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Indomethacin.]
[V04CH02, indigo carmine, Indomethacin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of gastrointestinal irritation can be increased when Desoxycortone is combined with Indomethacin.]
[J01DH03, ertapenem, Indomethacin may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of renal failure and hypertension can be increased when Indomethacin is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Indomethacin.]
[L04AB04, adalimumab, The metabolism of Indomethacin can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Indomethacin.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Indomethacin.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Indomethacin.]
[N06AB05, paroxetine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Indomethacin.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Indomethacin is combined with Clopidogrel.]
[P03AC04, permethrin, Indomethacin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Indomethacin may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[V03AH01, diazoxide, The therapeutic efficacy of Diazoxide can be decreased when used in combination with Indomethacin.]
[N06AA08, dibenzepin, The risk or severity of gastrointestinal bleeding can be increased when Dibenzepin is combined with Indomethacin.]
[R05DA08, pholcodine, Indomethacin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Foscarnet.]
[A03AA07, dicyclomine, Indomethacin may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Indomethacin.]
[J05AF02, didanosine, Indomethacin may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, The therapeutic efficacy of Pinacidil can be decreased when used in combination with Indomethacin.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Pioglitazone.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Indomethacin can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pirarubicin.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Indomethacin.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Indomethacin is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C08CA03, isradipine, The therapeutic efficacy of Isradipine can be decreased when used in combination with Indomethacin.]
[D07XC04, diflucortolone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Indomethacin.]
[N02BA11, diflunisal, The therapeutic efficacy of Diflunisal can be decreased when used in combination with Indomethacin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Indomethacin.]
[C02DB01, dihydralazine, The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Indomethacin.]
[C10AX09, ezetimibe, Indomethacin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Indomethacin.]
[C04AE04, dihydroergocristine, Indomethacin may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Indomethacin.]
[N02AA03, hydromorphone, Indomethacin may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Lenalidomide.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Indomethacin.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Indomethacin.]
[V03AB04, pralidoxime, Indomethacin may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[C08DB01, diltiazem, The therapeutic efficacy of Diltiazem can be decreased when used in combination with Indomethacin.]
[V03AB09, dimercaprol, Indomethacin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Indomethacin may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Proglumetacin.]
[G02AD01, dinoprost, The therapeutic efficacy of Dinoprost can be decreased when used in combination with Indomethacin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Indomethacin.]
[C05CA03, diosmin, The metabolism of Indomethacin can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, The metabolism of Diphenhydramine can be decreased when combined with Indomethacin.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Indomethacin.]
[C09AA06, quinapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Indomethacin is combined with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of gastrointestinal bleeding can be increased when Quinupramine is combined with Indomethacin.]
[C09AA05, ramipril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Ramipril.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sirolimus.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Reproterol.]
[S01AX06, resorcinol, Indomethacin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Natalizumab.]
[P03AA04, disulfiram, Indomethacin may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Indomethacin can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of hypertension can be increased when Indomethacin is combined with Risperidone.]
[R06AE09, levocetirizine, Indomethacin may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Indomethacin.]
[N01BB09, ropivacaine, Indomethacin may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, Indomethacin may increase the neuroexcitatory activities of Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sunitinib.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Indomethacin.]
[G04BE08, tadalafil, The therapeutic efficacy of Tadalafil can be decreased when used in combination with Indomethacin.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.]
[C02KX02, ambrisentan, The therapeutic efficacy of Ambrisentan can be decreased when used in combination with Indomethacin.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of adverse effects can be increased when Indomethacin is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Indomethacin may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of gastrointestinal bleeding can be increased when Dosulepin is combined with Indomethacin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Indomethacin is combined with Doxapram.]
[N06AA12, doxepin, The risk or severity of gastrointestinal bleeding can be increased when Doxepin is combined with Indomethacin.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Doxorubicin.]
[J01AA02, doxycycline, Indomethacin may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Indomethacin is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Indomethacin is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Indomethacin is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Indomethacin.]
[C10AA01, simvastatin, Indomethacin may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[V03AG05, sodium phosphate, The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Indomethacin.]
[A12CA02, sodium sulfate, Indomethacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Spirapril.]
[R03DA01, dyphylline, Indomethacin may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Indomethacin is combined with Sumatriptan.]
[V04CX07, edrophonium, Indomethacin may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Indomethacin may decrease the antihypertensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Indomethacin.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Indomethacin.]
[J01MA05, temafloxacin, Indomethacin may increase the neuroexcitatory activities of Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Temozolomide.]
[M01AC02, tenoxicam, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Indomethacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Indomethacin.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Terodiline.]
[C07AA16, tertatolol, Indomethacin may decrease the antihypertensive activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Tetryzoline.]
[N06AX14, tianeptine, The risk or severity of gastrointestinal bleeding can be increased when Tianeptine is combined with Indomethacin.]
[C09AA02, enalapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Indomethacin is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Indomethacin.]
[N03AX11, topiramate, Indomethacin may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Indomethacin.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Tramazoline.]
[C09AA10, trandolapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Trandolapril.]
[N05CC01, chloral hydrate, Indomethacin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Indomethacin.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be decreased when used in combination with Indomethacin.]
[J01MA04, enoxacin, Indomethacin may increase the neuroexcitatory activities of Enoxacin.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Ephedrine.]
[N06AX16, venlafaxine, Venlafaxine may increase the antiplatelet activities of Indomethacin.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Indomethacin can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Epirubicin.]
[C09AA15, zofenopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Indomethacin.]
[M01AB04, zomepirac, The risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.]
[N03AX15, zonisamide, The metabolism of Zonisamide can be decreased when combined with Indomethacin.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Indomethacin.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Carboplatin.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Indomethacin.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Indomethacin is combined with Iloprost.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Indomethacin is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Indomethacin is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Ergotamine.]
[N03AG01, valproic acid, The protein binding of Valproic acid can be decreased when combined with Indomethacin.]
[L03AX05, pidotimod, Indomethacin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, Erythromycin may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N05CD04, estazolam, Indomethacin may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, The excretion of Indomethacin can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The excretion of Estradiol can be decreased when combined with Indomethacin.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), The excretion of Indomethacin can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, Indomethacin may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA05, fluticasone, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Indomethacin.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Indomethacin.]
[V08CA03, gadodiamide, Indomethacin may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Gepefrine.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C01BD05, ibutilide, Indomethacin may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Ethosuximide.]
[M01AC06, meloxicam, The risk or severity of adverse effects can be increased when Indomethacin is combined with Meloxicam.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Etomidate is combined with Indomethacin.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Indomethacin.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Indomethacin.]
[J01MA08, fleroxacin, Indomethacin may increase the neuroexcitatory activities of Fleroxacin.]
[R06AX11, astemizole, Indomethacin may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, Indomethacin may decrease the excretion rate of Terfenadine which could result in a higher serum level.]
[P01AX07, trimetrexate, Indomethacin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Indomethacin may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of gastrointestinal bleeding can be increased when Fluvoxamine is combined with Indomethacin.]
[L02AE02, leuprolide, Indomethacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Indomethacin.]
[C10AA03, pravastatin, The excretion of Indomethacin can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, The metabolism of Indomethacin can be decreased when combined with Sodium aurothiomalate.]
[A05AA01, chenodeoxycholic acid, The metabolism of Indomethacin can be decreased when combined with Chenodeoxycholic acid.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Indomethacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dextran.]
[M05BA01, etidronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Etidronic acid.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dexrazoxane.]
[A02BA03, famotidine, The excretion of Famotidine can be decreased when combined with Indomethacin.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Indomethacin.]
[C08CA02, felodipine, The therapeutic efficacy of Felodipine can be decreased when used in combination with Indomethacin.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Indomethacin is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Salbutamol.]
[S01EE01, latanoprost, The therapeutic efficacy of Latanoprost can be decreased when used in combination with Indomethacin.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Fibrinolysin.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Indomethacin.]
[N07AX03, cevimeline, Indomethacin may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Indomethacin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The metabolism of Indomethacin can be decreased when combined with Flecainide.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Floctafenine.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Indomethacin can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Indomethacin.]
[V03AB25, flumazenil, Indomethacin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Indomethacin.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Indomethacin can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Indomethacin.]
[N06AA14, melitracen, The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Indomethacin.]
[H02AB03, fluocortolone, The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Indomethacin.]
[V03AZ01, ethanol, The risk or severity of gastrointestinal irritation can be increased when Ethanol is combined with Indomethacin.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Indomethacin.]
[S01CB05, fluorometholone, The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Indomethacin.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Indomethacin.]
[N05AF01, flupenthixol, The risk or severity of myelosuppression can be increased when Flupentixol is combined with Indomethacin.]
[N05CD01, flurazepam, Indomethacin may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Fluspirilene.]
[L02BB01, flutamide, Indomethacin may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Indomethacin may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Indomethacin may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Framycetin.]
[L01BC03, tegafur, Indomethacin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Indomethacin is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Indomethacin is combined with Furazolidone.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Indomethacin.]
[M05BA04, alendronic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.]
[N05CF04, eszopiclone, Indomethacin may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Gallopamil.]
[S01AD09, ganciclovir, The excretion of Indomethacin can be decreased when combined with Ganciclovir.]
[C10AB04, gemfibrozil, The metabolism of Indomethacin can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Indomethacin may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of hypertension can be increased when Cabergoline is combined with Indomethacin.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Liraglutide.]
[J05AG04, etravirine, The metabolism of Indomethacin can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Indomethacin is combined with Alfentanil.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Glipizide.]
[H04AA01, glucagon, The therapeutic efficacy of Glucagon can be decreased when used in combination with Indomethacin.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Indomethacin is combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, The therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Indomethacin.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be decreased when used in combination with Indomethacin.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Sorafenib.]
[C07AB09, esmolol, Indomethacin may decrease the antihypertensive activities of Esmolol.]
[M01CB04, aurothioglucose, Indomethacin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Indomethacin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Fosinopril.]
[S01EX01, guanethidine, The therapeutic efficacy of Guanethidine can be decreased when used in combination with Indomethacin.]
[L02AE03, goserelin, Indomethacin may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, The therapeutic efficacy of Haloperidol can be increased when used in combination with Indomethacin.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Indomethacin is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of hypertension can be increased when Indomethacin is combined with Quetiapine.]
[N06BX13, idebenone, Indomethacin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin aspart.]
[L01CE02, irinotecan, The risk or severity of neutropenia can be increased when Indomethacin is combined with Irinotecan.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Indomethacin.]
[C09CA01, losartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Indomethacin.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Heparin.]
[G03DC01, allylestrenol, Indomethacin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Indomethacin.]
[C01CE02, milrinone, Indomethacin may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Altretamine.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Indomethacin.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Indomethacin is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Indomethacin can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Indomethacin.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Perindopril.]
[C02DB02, hydralazine, Indomethacin may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Indomethacin.]
[D07AB02, hydrocortisone butyrate, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Indomethacin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Indomethacin.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Indomethacin.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Indomethacin.]
[V03AB33, hydroxocobalamin, Indomethacin may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Indomethacin is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydroxychloroquine.]
[B05AA07, hetastarch, Indomethacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Indomethacin is combined with Hydroxyurea.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Indomethacin.]
[M05BA07, risedronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibuprofen.]
[B05XA08, sodium acetate, Indomethacin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Sodium citrate.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Idarubicin.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Indomethacin is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of gastrointestinal bleeding can be increased when Imipramine is combined with Indomethacin.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Indomethacin is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Indomethacin.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Indomethacin is combined with Topotecan.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, Indomethacin may increase the neuroexcitatory activities of Pipemidic acid.]
[M01AG01, mefenamic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Indomethacin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Indomethacin.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be decreased when used in combination with Indomethacin.]
[A11HA07, inositol, Indomethacin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Indomethacin.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Indomethacin.]
[S01XA28, varenicline, Indomethacin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Eculizumab.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Indomethacin.]
[N05BA12, alprazolam, Indomethacin may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Indomethacin may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Vildagliptin.]
[C10AA06, cerivastatin, Indomethacin may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Indomethacin is combined with Anagrelide.]
[C07AA01, alprenolol, Indomethacin may decrease the antihypertensive activities of Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Indomethacin.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Indomethacin.]
[V03AB01, ipecac, Indomethacin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Indomethacin.]
[N06AA13, iprindole, The risk or severity of gastrointestinal bleeding can be increased when Iprindole is combined with Indomethacin.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Indomethacin.]
[N06AF05, iproniazid, The metabolism of Indomethacin can be decreased when combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Indomethacin is combined with Isocarboxazid.]
[P01AX06, atovaquone, The metabolism of Indomethacin can be decreased when combined with Atovaquone.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Indomethacin.]
[C09AA16, imidapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Indomethacin is combined with Isoflurane.]
[J04AC01, isoniazid, The metabolism of Indomethacin can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Indomethacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Indomethacin is combined with Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Exenatide.]
[D10BA01, isotretinoin, Indomethacin may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Indomethacin is combined with Isoxsuprine.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Bivalirudin.]
[S01AA24, kanamycin, Indomethacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Indomethacin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Indomethacin may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Indomethacin is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Prasugrel.]
[J02AB02, ketoconazole, Ketoconazole may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N05AH03, olanzapine, The metabolism of Indomethacin can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Indomethacin is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Indomethacin can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Indomethacin is combined with Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Indomethacin.]
[J01MB02, nalidixic acid, Indomethacin may increase the neuroexcitatory activities of Nalidixic acid.]
[C07AG01, labetalol, Indomethacin may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, Indomethacin may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AA05, deserpidine, The therapeutic efficacy of Deserpidine can be decreased when used in combination with Indomethacin.]
[A06AX03, lubiprostone, Indomethacin may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Indomethacin.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Indomethacin.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Lidoflazine.]
[S01AA21, amikacin, Indomethacin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Indomethacin can be decreased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Indomethacin is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of gastrointestinal bleeding can be increased when Lofepramine is combined with Indomethacin.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Lomustine.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Loperamide.]
[N05BA06, lorazepam, Indomethacin may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, Lovastatin may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Indomethacin.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Indomethacin is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Indomethacin may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Indomethacin may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Indomethacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Indomethacin.]
[N06AA21, maprotiline, Indomethacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Indomethacin.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mechlorethamine.]
[M02AA18, meclofenamic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be increased when it is combined with Indomethacin.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Dalteparin.]
[N05CH01, melatonin, The excretion of Indomethacin can be decreased when combined with Melatonin.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Indomethacin is combined with Melphalan.]
[N06DX01, memantine, Indomethacin may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Indomethacin may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Indomethacin is combined with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Indomethacin.]
[N01BB03, mepivacaine, Indomethacin may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Indomethacin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Indomethacin may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, The risk or severity of hypertension can be increased when Indomethacin is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Indomethacin is combined with Metaraminol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Metformin.]
[H01CB03, lanreotide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Lanreotide.]
[N07BC02, methadone, Indomethacin may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Metamfetamine.]
[J05AF05, lamivudine, Indomethacin may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, The excretion of Indomethacin can be decreased when combined with Methazolamide.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Metergoline.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Indomethacin is combined with Methimazole.]
[L01BA04, pemetrexed, Indomethacin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Indomethacin may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Indomethacin.]
[N05AA02, methotrimeprazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Methoxamine.]
[D05BA02, methoxsalen, Indomethacin may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Indomethacin is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Indomethacin.]
[V04CG05, methylene blue, The metabolism of Indomethacin can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Indomethacin is combined with Methylergometrine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Indomethacin is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Indomethacin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Indomethacin.]
[G03EK01, methyltestosterone, The excretion of Indomethacin can be increased when combined with Methyltestosterone.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Indomethacin.]
[A03FA01, metoclopramide, Indomethacin may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.]
[C07AB02, metoprolol, Indomethacin may decrease the antihypertensive activities of Metoprolol.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Indomethacin.]
[V04CD01, metyrapone, Indomethacin may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Indomethacin is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Indomethacin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Parnaparin.]
[N05CD08, midazolam, Indomethacin may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Indomethacin.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Tinzaparin.]
[J05AH01, zanamivir, Indomethacin may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Indomethacin.]
[J01AA08, minocycline, The excretion of Indomethacin can be decreased when combined with Minocycline.]
[D11AX01, minoxidil, The therapeutic efficacy of Minoxidil can be decreased when used in combination with Indomethacin.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indomethacin.]
[C01BD01, amiodarone, The metabolism of Indomethacin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Indomethacin.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Indomethacin.]
[A04AA05, palonosetron, Indomethacin may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Latamoxef.]
[L04AB05, certolizumab pegol, The metabolism of Indomethacin can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Indomethacin.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Ammonium chloride.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be decreased when combined with Indomethacin.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be decreased when combined with Indomethacin.]
[P01BA06, amodiaquine, The metabolism of Indomethacin can be decreased when combined with Amodiaquine.]
[G04CA04, silodosin, The metabolism of Silodosin can be decreased when combined with Indomethacin.]
[G03XC01, raloxifene, The metabolism of Raloxifene can be decreased when combined with Indomethacin.]
[N06AA17, amoxapine, The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Indomethacin.]
[N03AB05, fosphenytoin, The metabolism of Indomethacin can be decreased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Indomethacin.]
[C07AA12, nadolol, Indomethacin may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, Indomethacin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[J01CF06, nafcillin, The excretion of Indomethacin can be decreased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Naloxone can be decreased when combined with Indomethacin.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be decreased when combined with Indomethacin.]
[L04AC03, anakinra, The metabolism of Indomethacin can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Indomethacin.]
[M02AA12, naproxen, The risk or severity of adverse effects can be increased when Indomethacin is combined with Naproxen.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N06AX21, duloxetine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Indomethacin.]
[N04BX01, tolcapone, Indomethacin may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Indomethacin is combined with Docetaxel.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Indomethacin is combined with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Repaglinide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Indomethacin is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of hypertension can be increased when Indomethacin is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Amphotericin B.]
[S01AA19, ampicillin, Indomethacin may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Indomethacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Indomethacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Indomethacin.]
[C09CA07, telmisartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Indomethacin.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Indomethacin.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be decreased when combined with Indomethacin.]
[C01CE01, inamrinone, Indomethacin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Indomethacin.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Indomethacin is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Indomethacin can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Nicergoline.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Indomethacin.]
[C08CA05, nifedipine, Indomethacin may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Niflumic acid.]
[C08CA06, nimodipine, The therapeutic efficacy of Nimodipine can be decreased when used in combination with Indomethacin.]
[C08CA07, nisoldipine, The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Indomethacin.]
[C08CA08, nitrendipine, The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Indomethacin.]
[R07AX01, nitric oxide, Indomethacin may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Indomethacin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Indomethacin may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Indomethacin may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Indomethacin.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Indomethacin is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Norepinephrine.]
[S01AE02, norfloxacin, Indomethacin may increase the neuroexcitatory activities of Norfloxacin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N06AA10, nortriptyline, The risk or severity of gastrointestinal bleeding can be increased when Nortriptyline is combined with Indomethacin.]
[R05DA07, noscapine, The metabolism of Indomethacin can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Indomethacin is combined with Eptifibatide.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Indomethacin is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reviparin.]
[H01CB02, octreotide, The risk or severity of hypoglycemia can be increased when Octreotide is combined with Indomethacin.]
[S02AA16, ofloxacin, Indomethacin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Indomethacin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Indomethacin.]
[N06AA05, opipramol, The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Indomethacin.]
[N02AA02, opium, Indomethacin may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Indomethacin is combined with Orciprenaline.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Ancrod.]
[G04CA02, tamsulosin, Indomethacin may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Indomethacin can be decreased when combined with Ouabain.]
[M05BA08, zoledronic acid, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Zoledronic acid.]
[J01CF04, oxacillin, Indomethacin may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, The metabolism of Indomethacin can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Indomethacin may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, Indomethacin may increase the neuroexcitatory activities of Oxolinic acid.]
[C07AA02, oxprenolol, Indomethacin may decrease the antihypertensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Indomethacin is combined with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxyphenbutazone.]
[S01AA04, oxytetracycline, The excretion of Oxytetracycline can be decreased when combined with Indomethacin.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Indomethacin.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Indomethacin.]
[N05AH05, asenapine, The risk or severity of hypertension can be increased when Indomethacin is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Danaparoid.]
[N02AX06, tapentadol, The metabolism of Tapentadol can be decreased when combined with Indomethacin.]
[J04AB30, capreomycin, Indomethacin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[H02AB05, paramethasone, The risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Indomethacin.]
[C02KC01, pargyline, The therapeutic efficacy of Pargyline can be decreased when used in combination with Indomethacin.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Paromomycin.]
[J01MA03, pefloxacin, Indomethacin may increase the neuroexcitatory activities of Pefloxacin.]
[G04BD11, fesoterodine, Indomethacin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Indomethacin may decrease the antihypertensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Penfluridol.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Penicillamine.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Indomethacin.]
[J01CE09, penicillin G procaine, Indomethacin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indomethacin.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indomethacin.]
[N05CA01, pentobarbital, Indomethacin may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Pentostatin.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Indomethacin is combined with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Indomethacin is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Perhexiline.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Indomethacin.]
[N02BE03, phenacetin, The excretion of Indomethacin can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Indomethacin is combined with Phenelzine.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Indomethacin can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Indomethacin.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Indomethacin.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be decreased when used in combination with Indomethacin.]
[M02AA01, phenylbutazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Indomethacin is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Indomethacin.]
[L04AB06, golimumab, The metabolism of Indomethacin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Indomethacin may increase the neuroexcitatory activities of Levofloxacin.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Indomethacin.]
[B02BA01, vitamin K1, Indomethacin may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cidofovir.]
[C08CX01, mibefradil, The therapeutic efficacy of Mibefradil can be decreased when used in combination with Indomethacin.]
[C07AA03, pindolol, Indomethacin may decrease the antihypertensive activities of Pindolol.]
[C10AA05, atorvastatin, Indomethacin may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Indomethacin.]
[J05AE01, saquinavir, Indomethacin may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[N06BX03, piracetam, Indomethacin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Indomethacin.]
[S01BC06, piroxicam, The risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Indomethacin is combined with Cefditoren.]
[J01MA11, grepafloxacin, Indomethacin may increase the neuroexcitatory activities of Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Indomethacin is combined with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Indomethacin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Indomethacin.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Alteplase.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Rosiglitazone.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Indomethacin.]
[L04AC08, canakinumab, The metabolism of Indomethacin can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Indomethacin is combined with Polymyxin B.]
[C03AA05, polythiazide, The therapeutic efficacy of Indomethacin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Indomethacin can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Indomethacin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Indomethacin.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Indomethacin.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Insulin lispro.]
[C10AA08, pitavastatin, Indomethacin may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Indomethacin may decrease the antihypertensive activities of Practolol.]
[C02CA01, prazosin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Indomethacin.]
[S03BA02, prednisolone, The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Indomethacin.]
[H02AB07, prednisone, The risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Indomethacin.]
[M02AA16, feprazone, The risk or severity of adverse effects can be increased when Indomethacin is combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Prenylamine.]
[N03AA03, primidone, The metabolism of Indomethacin can be increased when combined with Primidone.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[C01BA02, procainamide, Indomethacin may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Indomethacin is combined with Procarbazine.]
[C10AB05, fenofibrate, Indomethacin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N05AA03, promazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Promazine.]
[R06AD02, promethazine, The metabolism of Indomethacin can be decreased when combined with Promethazine.]
[C01BC03, propafenone, Indomethacin may decrease the antihypertensive activities of Propafenone.]
[A03AB05, propantheline, Indomethacin may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Indomethacin.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Indomethacin is combined with Propiomazine.]
[N01AX10, propofol, The metabolism of Propofol can be decreased when combined with Indomethacin.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Indomethacin.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Indomethacin is combined with Propylthiouracil.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Indomethacin is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Indomethacin.]
[N06AA11, protriptyline, The risk or severity of gastrointestinal bleeding can be increased when Protriptyline is combined with Indomethacin.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypertension can be increased when Indomethacin is combined with Aripiprazole.]
[N07XX07, dalfampridine, Indomethacin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Indomethacin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Indomethacin may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Indomethacin.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Indomethacin.]
[C01BA01, quinidine, Indomethacin may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Quinine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Indomethacin.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Rescinnamine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[J05AP01, ribavirin, Indomethacin may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[S01XA26, riboflavin, The excretion of Indomethacin can be decreased when combined with Riboflavin.]
[J04AB02, rifampin, Rifampicin may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Indomethacin is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Indomethacin is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Sulfasalazine can be decreased when used in combination with Indomethacin.]
[S01BC08, salicylic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylic acid.]
[N05CA06, secobarbital, Indomethacin may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Indomethacin is combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Indomethacin is combined with Obinutuzumab.]
[J01GB08, sisomicin, Indomethacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Indomethacin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Indomethacin.]
[V04CC01, sorbitol, Indomethacin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Indomethacin may decrease the antihypertensive activities of Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Indomethacin is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Indomethacin.]
[C03DA01, spironolactone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Spironolactone.]
[C01DA14, isosorbide mononitrate, Indomethacin may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Indomethacin may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of adverse effects can be increased when Indomethacin is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
